Phio Pharmaceuticals Announces Publication in Frontiers in Immunology
Portfolio Pulse from
Phio Pharmaceuticals Corp. announced the publication of a manuscript in Frontiers in Immunology, showcasing preclinical data for their INTASYL compound, PH-762, which is in clinical development for advanced cutaneous malignancies.
December 12, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phio Pharmaceuticals' publication in a reputable journal highlights promising preclinical data for PH-762, potentially boosting investor confidence and stock price.
The publication in a reputable journal provides validation for Phio's technology and its potential in cancer treatment, likely increasing investor interest and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100